Revenio Group Oyj (0KFH) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Revenue Group Q1 2025 earnings call. My name is Jouni Toijala. I'm the Group CEO. And then, as always, we have here as well Robin Pulkkinen, our CFO. Plan for today is to go through the highlights for the Q1, and I'll cover that part, and then Robin is going to continue going through the financials for the Q1, and then shareholders and financial guidance for 2025, and then we finish up for the Q&A. But let's... kick off extremely good start for the first quarter. The Q1 was very strong for us in terms of the sales and profitability. Net sales was 26.1 million, up 10.5% from the previous year, 23.6 million euros. If we look the currency adjusted growth So that was 12%. EBIT on good level, 6.6 million, 25.4% out from revenue. If we then go more to the sales split. So imaging and tonometer business grew in every region during the Q1. So we got the growth from US, APAC, Europe, Middle East, Africa, LATAM and Canada. Then if we do a bit more deeper dive into the specific countries, so in APAC region, China grew very strongly, same for India as well. Then we got the good growth also from Europe and Canada. Then I'm sure that there's a lot of questions related to the outlook and the pipeline. So as of today, we see a healthy pipeline from the sales perspective in the USA as well. Then if going through a bit more detailed, the actual product lines. So from the tonometer perspective, Probes selling really well. I see 200 selling really well. And then we launched also the new Tonovet Pro version during the second half of 2024. So that has been performing extremely well as well. Then on the fundus imaging side, more or less the same story than in the last quarter. So DRS plus business growing well and the aid on product family growing extremely wel...